As well as the high rate of KRAS activating mutations, sequence analysis has shown that PDACs demonstrate a mixture of tumor suppressor gene mutations, with TP53 being mutated or inactivated in 75% of PDAC and mutant TP53 being shown to drive pancreatic cancer (48). Here, TP53 is linked to neoplasm.